Wednesday , November 20 2019
Home / BUSINESS / Sun Pharma comes up with psoriasis treatment drug ‘ILUMYA’ in US

Sun Pharma comes up with psoriasis treatment drug ‘ILUMYA’ in US

Sun Pharmaceutical Industries has launched its plaque psoriasis treatment drug ‘ILUMYA’ (tildrakizumab-asmn) 100 mg/mL in the United States. ILUMYA is an injectable interleukin-23 (IL-23) inhibitor approved by the USFDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

ILUMYA injections are administered by a healthcare provider every 12 weeks, following starter doses at Week 0 and Week 4.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.